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Background—Glucose and insulin levels are associated with left ventricular mass (LVM) in insulin-
resistant individuals .The association between obesity and cardiovascular disease is well 
established, and up to 60% of overweight or obese patients have hypertension. Dietary interventions 
associated with modest weight loss are effective in controlling blood pressure and in reducing use 
of antihypertensive drug therapy in overweight and obese patients. However, long-term 
maintenance of weight loss is achieved only in a small proportion of patients.  Antihypertensive 
drugs have different effects on glucose and insulin metabolism (GIM) and on LVM. . Consequently, 
antihypertensive drug therapy is often necessary in addition to weight loss interventions. Few 
studies have investigated different antihypertensive drugs, specifically in overweight and obese 
patients with hypertension. To evaluate whether the effects of antihypertensive therapy on LVM are 
associated with its effects on GIM, we compared the effects of telmisartan and aliskiren on these 
parameters in a group of insulin-resistant, obese hypertensives. Methods and Results—A total of 41 
obese, nondiabetic hypertensives who were aged 55±6 years, had a body mass index of 32.8±5.0 
kg/m
2
, were free of coronary or valvular heart disease, and had normal LV function were 
randomized to treatment with telmisartan (n=21) or aliskiren(n=20). Echocardiographic LVM 
corrected for height (LVM/height) , GIM (3-hour intravenous glucose tolerance test) and 
albuminuria were measured after 4 to 6 weeks of washout and 6 months of treatment. Baseline 
characteristics were similar in both groups. Telmisartan and aliskiren effectively reduced blood 
pressure (from 149±13/98±4 to 127±8/82±6 mm Hg and from 148±9/98±4 to 129±9/82±6 mm Hg, 
respectively, for the telmisartan and aliskiren groups; P=0.002). Telmisartan significantly worsened 
GIM parameters, fasting glucose levels (5.3±0.9 to 6.0±1.5 mmol/L; P=0.003), fasting insulin 
levels (121±121 to 189±228 pmol/L; P=0.03), and most other relevant metabolic measures (P<0.05 
for all). Aliskiren did not affect GIM. Telmisartan did not affect LVM/height (119±12 to 120±17 
g/m; P=0.8), whereas aliskiren significantly reduced LVM/height (120±13 to 111±19 g/m; P=0.04). 
Upon BP control, microalbuminuria was markedly decreased in both group (P=0.002). 
CONCLUSIONS: In the absence of weight loss, most patients required combined antihypertensive 
therapy to control their BP, regardless of their body fat distribution pattern. Optimal target BP and 
normal albuminuria were achieved in the group as a whole and in both obese patient groups, while 
benefits to cardiac structure were of a smaller magnitude. High-risk, overweight/obese patients with 
hypertension and type 2 diabetes, Telmisartan  provides significantly greater BP lowering versus 
Aliskiren throughout the 24-hour dosing interval, particularly during the hazardous early morning 
hours. Therefore In obese, hypertensive individuals, adequate and similar blood pressure control 
was achieved with telmisartan and aliskiren ;however, aliskiren but not telmisartan was associated 
with a more favorable GIM profile and led to a significant regression of LVM.  
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Background We attempted to test the hypothesis that chronic angiotensin II type 1A receptor blockade 
(ARB)alters myocardial collagen turnover leading to an improvement of diastolic dysfunction in diabetic 
patients. While the mechanisms underlying  it and the changes in left ventricular systolic function, diastolic 
function, and mitral regurgitation during long-term therapy remain unclear. On the other hand although 
echocardiography is important for making the diagnosis of left ventricular dysfunction, its cost and lack of 
availability limit its use as a routine screening test. B-natriuretic peptide(BNP) levels accurately reflect 
ventricular pressure, and preliminary studies with a rapid assay have found that levels are sensitive and 
specific for diagnosing heart failure in patients with dyspnea.  We hypothesized that BNP levels obtained 
through the use of a rapid assay should correlate with echocardiographic abnormalities of ventricular 
function .Objective To identify the clinical and functional effects of telmisartan, focusing on diastolic 
function , mitral regurgitation variations.and and Plasma BNP Level .Methods and Results Fifty two  type 2 
diabetic hypertensies who were aged 67±5 years ,were divided into 2 groups: 30 treated with telmisartan 
for 6 months, and 22 without telmisartan, as controls. Doppler mitral flow velocity pattern and biomarkers of 
BNP levels were measured by a point-of-care immunoassay; cardiologists assessing left ventricular function 
were blinded to the assay results. They were assessed before and after ARB telmisartan during a 6-month 
period .Patients were grouped into those with normal ventricular function, systolic dysfunction only, 
diastolic dysfunction only, and both systolic and diastolic dysfunction. After 6 months of treatment with 
telmisartan, left ventricular ejection fraction had increased from 24% ± 7% to 29% ± 9% (P < .0001); this 
change was caused by a reduction in end-systolic volume index (106 ± 41 vs 93 ± 37 ml/m
2
; P < .0001). 
Deceleration time of early diastolic filling increased (134 ± 74 vs 196 ± 63 ms; P < .0001). Seventeen of the 
28patients with demonstrated improvement of left ventricular diastolic filling moved from having a 
restrictive filling pattern to having a normal or pseudonormal left ventricular filling pattern. In the control 
group, no signigicant changes in deceleration time of early diastolic filling were found (139 ± 74 vs 132 ± 45 
ms; P = not significant). The effective regurgitant orifice area decreased significantly in the telmisartan 
group but not in the control group. These changes were associated with a significant reduction of the mitral 
regurgitant stroke volume in the telmisartan group (50 ± 25 vs 16 ± 13 ml; P < .0001) but not in the control 
group (57 ± 29 vs 47 ± 24 ml; P = not significant). These changes of mitral regurgitation were closely 
associated with significant improvement of forward aortic stroke volume (r = −.57, P < .0001). These 
findings were not observed in patients in the control group. The mitral E/A ratio increased from 0.65±0.11 to 
0.75±0.19 following ARB. Mean (± SD). BNP concentration was 416 ± 413 pg/ml in the 28 patients 
diagnosed with abnormal left ventricular function, compared with 30 ± 36 pg/ml in the 20 patients with 
normal left ventricular function. 2 Patients with both systolic and diastolic dysfunction had the highest levels 
(675 ± 423 pg/ml). BNP levels were unable to differentiate systolic vs. diastolic dysfunction. In patients with 
symptoms of heart failure and normal systolic function, BNP levels >57 pg/ml had a positive predictive 
value of 100% for diastolic abnormalities. The plasma BNP concentration slightly decreased following 
chronic ARB, but the difference did not reach the statistical significance. The change in left ventricular 
chamber stiffness did not correlate with the change in BNP level(r=0.08, p=NS), Conclusions Chronic ARB 
improves diastolic dysfunction in diabetic hypertensives. A simple, rapid test for BNP levels can reliably 
predict the presence or absence of left ventricular dysfunction on echocardiogram. 
 
 
